<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096820</url>
  </required_header>
  <id_info>
    <org_study_id>6026618</org_study_id>
    <nct_id>NCT04096820</nct_id>
  </id_info>
  <brief_title>Uromune in Treating Recurrent Urinary Tract Infections in Women</brief_title>
  <official_title>Protocol 19-01: Canadian, Single Centre, Pilot, Open Label Study to Evaluate the Efficacy and Safety of the Bacterial Vaccine Uromune in Treating Recurrent Urinary Tract Infections in Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effectiveness and safety of the vaccine Uromune in Canadian women with
      recurrent urinary tract infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposal is for a real life clinical practice study in which female participants with a
      predefined history of recurrent UTIs in the previous year will be treated with 3 months of
      oral vaccine with a further 9 months of follow-up. The primary outcome will be no UTI in the
      12 months following initiation of the vaccine (definition of a responder). A clinically
      significant and important outcome will be defined as a responder rate of 50% (50% of
      participants who had at least 3 UTIs in the previous year reporting no UTIs after therapy
      initiated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Responder</measure>
    <time_frame>12 months</time_frame>
    <description>Participant considered complete responder if no UTI requiring antibiotics reported 12 months since initiating therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder Rate</measure>
    <time_frame>12 months</time_frame>
    <description>The number of UTI in individual participants requiring antibiotics in the 12 months after starting therapy will be compared to the number of UTIs requiring antibiotics before therapy is initiated (number over previous 12 months or 2 X the number over the preceding 6 months).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Recurrent Uti</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uromune will be taken by the participant for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Uromune</intervention_name>
    <description>2 sprays of vaccine under the tongue for 90 days. Liquid is to held under tongue for 2 minutes without swallowing.</description>
    <arm_group_label>Open Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Can provide written consent and willingness to comply with all aspects of study
             treatment and study requirements.

          -  Individuals who have had at least 3 episodes of a UTI in the past 12 months or 2 UTI
             episodes in the past 6 months. At least one of the UTI episodes must be associated
             with a positive urine culture with a traditional uropathogen including Escherichia
             coli, Proteus spp. Staphyloccous sp. Enterococcus sp. Klebsiella sp. or Pseudomonas
             aeruginosa.

          -  Post-menopausal for a minimum of 1 year or negative pregnancy test if participant is
             of child bearing potential and agreement to acceptable contraceptive use from
             Screening Visit 1 to final follow up visit if participant is sexually active.
             Medically acceptable methods of contraception include hormonal contraception (i.e.
             estrogen, and/or progesterone or preparations that contain a combination of these
             hormones), non-hormonal intrauterine device or double barrier method (i.e. condom with
             foam or vaginal spermicidal suppository, or diaphragm with spermicide) or vasectomy of
             sole sexual partner. Complete abstinence alone can be used as a method of
             contraception.

          -  Free of a urinary tract infection at the time of trial inclusion.

        Exclusion Criteria:

          -  History of bladder tumours including uterine, cervical, vaginal or urethral cancer.

          -  Worrisome post-voiding residual (investigator's discretion).

          -  Infection related to urinary lithiasis.

          -  Any immunological disease requiring active therapy.

          -  Currently receiving Immunotherapy.

          -  Taking any prophylactic antibiotics at screening. Any prophylactic antibiotics must be
             stopped the day of the screening visit.

          -  Any known intolerance to the ingredients of the UromuneÂ® Immunotherapy.

          -  Have any other condition or disease which, in the opinion of the investigator, could
             compromise participant safety or interfere with the participant's participation in the
             study or in the evaluation of the study results.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Curtis Nickel, MD, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Urology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet Clark-Pereira</last_name>
    <phone>613-548-7805</phone>
    <email>jmc2@queensu.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>J. Curtis Nickel, MD, FRCSC</last_name>
    <phone>613-548-2497</phone>
    <email>jcn@queensu.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for Advanced Urological Research</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Clark-Pereira</last_name>
      <phone>(613) 548-7805</phone>
      <email>jmc2@queensu.ca</email>
    </contact>
    <investigator>
      <last_name>J. Curtis Nickel, MD FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chris Doiron, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. J. Curtis Nickel</investigator_full_name>
    <investigator_title>Professor or Urology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT04096820/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT04096820/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

